Patents by Inventor Mark K. Bennett

Mark K. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20210361649
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: March 4, 2021
    Publication date: November 25, 2021
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10940148
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • COMBINATION THERAPY WITH PEPTIDE EPOXYKETONES
    Publication number: 20200254051
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Application
    Filed: February 14, 2020
    Publication date: August 13, 2020
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • Combination therapy with peptide epoxyketones
    Patent number: 10596222
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 24, 2020
    Assignee: ONYX THERAPEUTICS, INC.
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20190231776
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 1, 2019
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10258619
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with glutaminase inhibitors
    Patent number: 10195197
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • Combination Therapy with Glutaminase Inhibitors
    Publication number: 20180055842
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 1, 2018
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • Combination Therapy with Peptide Epoxyketones
    Publication number: 20170151305
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Application
    Filed: November 2, 2016
    Publication date: June 1, 2017
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • Compounds for enzyme inhibition
    Patent number: 9657058
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: May 23, 2017
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
    Publication number: 20170095473
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Application
    Filed: October 4, 2016
    Publication date: April 6, 2017
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Combination therapy with peptide epoxyketones
    Patent number: 9511109
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: December 6, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS
    Publication number: 20160287564
    Abstract: In some aspects, the invention relates to a method of treating cancer, a myeloproliferative disease, an immunological disease, a neurological disease, or a viral infection, comprising orally administering a compound of formula I, formula II, formula III, formula IV, formula V, and/or formula VI, wherein the compound is administered with a meal (e.g., with food as defined herein) or in fed mode.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 6, 2016
    Inventors: Matthew I. Gross, Mark K. Bennett, Christopher Molineaux
  • Compounds for immunoproteasome inhibition
    Patent number: 9359398
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: June 7, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Mark K. Bennett
  • COMPOUNDS FOR ENZYME INHIBITION
    Publication number: 20150353601
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: January 7, 2015
    Publication date: December 10, 2015
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • In vivo production of cyclic peptides for inhibiting protein-protein interaction
    Patent number: 9040462
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 26, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
    Publication number: 20150004134
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: December 3, 2013
    Publication date: January 1, 2015
    Applicant: CALITHERA BIOSCIENCES, INC.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
  • Combination Therapy with Peptide Epoxyketones
    Publication number: 20140364375
    Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett
  • Collagen production compound
    Patent number: 8895034
    Abstract: A topical skin care lotion includes materials for supplementing the production of collagen I and III includes a base of lipophillic or lipophobic material and at least one amino acid. The amino acids are alanine and glycine. Other components of the lotion include iron, vitamin C, manganese, silica and cherry fruit extract. Together, these components assist the body with the production of collagen and promote healing of damaged skin. Antioxidants are also provided to protect the skin from oxidative stress by ultraviolet sunlight and environmental hazards.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: November 25, 2014
    Inventor: Mark K. Bennett
  • Combination therapy with peptide epoxyketones
    Patent number: RE47954
    Abstract: ABSTRACT The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 21, 2020
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Christopher J. Kirk, Susan D. Demo, Mark K. Bennett